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a b s t r a c t
The dysfunction and loss of basal forebrain cholinergic neurons and their cortical projections are among
the earliest pathological events in the pathogenesis of Alzheimer’s disease (AD). The evidence pointing
to cholinergic impairments come from studies that report a decline in the activity of choline acetyltrans-
ferase (ChAT) and acetylcholine esterase (AChE), acetylcholine (ACh) release and the levels of nicotinic
and muscarinic receptors, and loss of cholinergic basal forebrain neurons in the AD brain. Alzheimer’s
disease pathology is characterized by an extensive loss of synapses and neuritic branchings which are
the dominant scenario as compared to the loss of the neuronal cell bodies themselves. The appearance
of cholinergic neuritic dystrophy, i.e. aberrant ﬁbers and ﬁber swelling are more and more pronounced
during brain aging and widely common in AD. When taking amyloid- (A) deposition as the ultimate
causal factor of Alzheimer’s disease the role of A in cholinergic dysfunction should be considered. In
that respect it has been stated that ACh release and synthesis are depressed, axonal transport is inhib-
ited, and that ACh degradation is affected in the presence of A peptides. -Amyloid peptide 1–42, the
principal constituent of the neuritic plaques seen in AD patients, is known to trigger excess amount of
glutamate in the synaptic cleft by inhibiting the astroglial glutamate transporter and to increase the
intracellular Ca2+ level. Based on the glutamatergic overexcitation theory of AD progression, the function
of NMDA receptors and treatment with NMDA antagonists underlie some recent therapeutic applica-
tions. Memantine, a moderate afﬁnity uncompetitive NMDA receptor antagonist interacts with its target
only during states of pathological activation but does not interfere with the physiological receptor func-
tions. In this study the neuroprotective effect of memantine on the forebrain cholinergic neurons against
A42 oligomers-induced toxicity was studied in an in vivo rat dementia model. We found that meman-
tine rescued the neocortical cholinergic ﬁbers originating from the basal forebrain cholinergic neurons,
attenuatedmicroglial activation around the intracerebral lesion sides, and improved attention andmem-
ory of A42-injected rats exhibiting impaired learning and loss of cholinergic innervation of neocortex.
Abbreviations: A, beta amyloid; A42, beta amyloid peptide 1–42; ACh,
cetylcholine; AChE, acetylcholinesterase; AD, Alzheimer’s disease; APP/PS1, amy-
oid precursor protein/presenilin 1; BACE, beta-site APP-cleaving enzyme; BFChS,
holinergic basal forebrain system;ChAT, choline acetyltransferase;GAP-43, growth
ssociated protein 43; HDB, horizontal limb of the diagonal band of Broca;
PS, lipopolysaccharide; LTP, long-term potentiation; NFT, neuroﬁbrillary tangles;
AChR, nicotinic acetylcholine receptor; NMDA, N-methyl-d-aspartate; mAChR,
uscarinic acetylcholine receptor; MBN, nucleus basalis magnocellularis; PKC, pro-
ein kinase C; PLC, phospholipase C; VAChT, vesicular ACh transporter; VDB, vertical
imb of the diagonal band of Broca.
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1. Introduction
1.1. Organization of the basal forebrain cholinergic system
(BFChS)
The cholinergic innervation of the cortical mantle, olfactory
bulb, hippocampus and amygdala in the mammalian brain origi-
nates from cholinergic cell groups in the basal forebrain andmedial
septal region. Its anatomical organization of its connectivity has
well been studied with various methods like staining of cells and
projection ﬁberswith the cholinergicmarkers acetylcholinesterase
and choline acetyltransferase [30,75], next to visualizing projection
patterns with intra-axonal tract tracing methods [39]. Basal fore-
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agnocellularis (MBN) in the rodent brain or the human homo-
ogue nucleus basalis of Meynert sends well developed projections
o basically all layers of all cortical regions. The MBN and its subdi-
isions send their efferents to the entire cortical mantle although a
lear antero-posterior organization can be distinguished. Anterior
BN innervates prefrontal and olfactory regions, and noteworthy
lso the amygdaloid complex. Themore intermediate andposterior
BN subdivisions send their efferents to themoreneocortical areas
39]. The general innervation pattern originating from the MBN
omplex is characterizedbyhigh terminalﬁberdensities inall corti-
al layers but appears to be particularly dense in layer V. Themedial
eptum, vertical limb (VDB) and medial part of the horizontal limb
f the diagonal band of Broca (HDB) provides the cholinergic inner-
ations to the hippocampal regions including entorhinal cortex
ivisions [19] whereas the lateral part of the HDB sends their out-
ut to the olfactory bulb. Themedial HDB is also amajor cholinergic
ource of the prefrontal cortex [19].
Important from a functional point of view were the more
etailed observations on how presynaptic terminals associate with
heir target structures. When anterogradely ﬁlled with tracer com-
ounds like Phaseolus vulgaris leucoagglutinin positively labeled
erminal boutons were seen making contact with dendritic or cell
oma structures of the receptive nerve cells in the innervated
egions. These synaptic contacts could not only be observed with
ight microscopic resolution but also be conﬁrmed with electron-
icroscopy [18]. Double labeling electronmicroscopy furthermore
evealed presynaptic MBN terminals making contact with post-
ynaptic spines positively labeled for muscarinic receptor protein
18,69,70]. Another major detail was the direct contact of presy-
aptic boutons making contact with mainly microvascular and
apillary structures in all innervated forebrain areas [21]. However
ore closer study of cholinergic innervations of cortical microves-
el reveal that cholinergic terminals do not synapse directly on
ascular endothelium or the surrounding basement membrane
ut to the adjacent perivascular astrocytic endfeet that proved to
e endowed with muscarinic receptors [25]. We think that such
etailed anatomical information is critical for understanding the
onsequences of cholinergic breakdown as occurs in Alzheimer’s
isease. These observations arehighlightedherewith respect to the
rominent loss of cholinergic forebrain innervations in Alzheimer’s
isease and in aging to be further discussed elsewhere in this jour-
al see also [11,20,39].
.2. Effects of aging on the basal forebrain cholinergic system
BFChS)
Aging has a profound effect on the integrity of the forebrain
ber patterns that ﬁnd their origin in general modifying transmit-
er systems such as the serotonergic, noradrenergic, dopaminergic
nd cholinergic cellgroups inmidbrain and basal forebrain.Wewill
ot go into great detail in the present report. In view of the scope
f the theme of this special issue we will conﬁne our interest to the
ate of the cholinergic basal forebrain system (BFChS) and its inner-
ation networks in the corticalmantle and associated regions. Next
o the fate of these ﬁber pathways during aging in general we will
hortly address the profound loss of cholinergic presynaptic wiring
n Alzheimer’s disease.
During normal aging, that is aging not accompanied by overt
ehavioral or cognitive dysfunctions associated with the choliner-
ic forebrain system, clear changes can be discerned with respect
o the anatomical integrity of ﬁber pathways penetrating the vari-
us cortical layers, a phenomenon that is not limited to the cortical
egions but affects structures like thalamus and brainstem as well
20]. Characteristic for such aging related changes are conspicuous
eadlike swellings within the cholinergic ﬁbers. Electronmicro-
copic observations of such enlarged thickenings reveal swollenesearch 221 (2011) 594–603 595
axonal varicosities that often occurred in grape-like clusters. Occa-
sionally swollen presynaptic endings were encountered but most
of such thickenings were axonal swellings. The fact that we could
induce such thickened ﬁber swellings by applying damage to the
parent cell bodies point to an intermediary state of slow cell and
ﬁber degeneration of affected neurons and their projecting axons
[21,20].
1.3. The BFChS in Alzheimer’s disease
The dysfunction and loss of basal forebrain cholinergic neurons
and their cortical projections are among the earliest pathological
events in pathogenesis of Alzheimer’s disease [62]. In addition to
the extensive neuronal loss in these brain regions, the evidence
pointing to cholinergic impairments come from studies that report
a decline in the activity of choline acetyltransferase (ChAT) and
acetylcholine esterase (AChE), acetylcholine (ACh) release and the
levels of nicotinic and muscarinic receptors in AD brain [30,50,3].
When taking amyloid- deposition as the ultimate causal factor of
Alzheimer’s disease we should consider the role of A in choliner-
gic dysfunction. In that respect it has been stated that ACh release
and synthesis are depressed and ACh degradation is affected in
the presence of A peptides [7]. Although AChE levels are reduced
in AD brain, its activity is increased around plaques and in neu-
roﬁbrillary tangles (NFT) bearing neurons [67]. The increase in
activity of this enzyme is likely to be due to an indirect effect
of A (notably of A42), mediated via oxidative stress [45], via
voltage dependent calcium channels or via nicotinic acetylcholine
receptors (nAChRs) of the Ca2+ permeable 7 subtype [16]. This
latter phenomenon links this A effect to overexcitation of the
nerve cell when exposed to amyloid peptides, which may boost the
intracellular calcium accumulation induced by overstimulation by
glutamate in the amyloid deposition domain [73,37]. Muscarinic
AChR signaling pathways are also impaired by A. In APP/PS1
double-transgenicmice, thedensityofmAChRswas lowered,which
undergoes an age related decline that is not attributable to mAChR
depletion alone, but rather to a malfunction in mAChR-G-protein
coupling [40]. Such a mAChR decline may play a substantial role
in the cognitive dysfunctions of the BFChS in AD. Interestingly, it
was reported thatAChEpromotesA aggregation, possibly through
A-AChE interaction by a hydrophobic environment close to the
peripheral anionic binding site of the enzyme, thus promoting
ﬁbril formation [29]. When AChE becomes associated with amy-
loid ﬁbrils, some of its characteristics, like sensitivity to low pH,
change. Therefore, AChE might play an important role in neurotox-
icity induced by A. This notion is supported by the observation
that A-AChE complexes are more toxic than amyloid ﬁbrils alone
[2].
However, the relationship between A and the cholinergic
system is not unidirectional. There is a considerable amount of
evidence that cholinergic dysfunction inﬂuences APP metabolism
and consequent A production. For example, it has been shown
that stimulation of the M1 and M3 muscarinic receptor subtypes
increased the release of APP through activation of PLC/protein
kinase C (PKC) cascade [52]. BACE (beta-site APP-cleaving enzyme)
expression was also increased by activation of these receptor sub-
types [77].
1.4. Aberrant sprouting of cholinergic ﬁbers, inhibition of axonal
transport and neuritic pathology in AD
Alzheimer’s disease (AD) pathology is characterized by an
extensive loss of synapses and neuritic branchings which are the
dominant scenario as compared to the loss of the neuronal cell
bodies themselves [4,5]. However, the size of cholinergic neuronal
cell bodies is getting smaller with age [46], thus neuronal cell
596 C. Nyakas et al. / Behavioural Brain Research 221 (2011) 594–603





































ncetylcholine esterase (AChE) histochemical technique. Note that in the Alzheimer’
marked by white arrows), which might be considered as aberrant en passant syna
he control and Alzheimer’s cases, although much less are present in latter case. Sca
ody shrinkage is another sign of pathology. The breakdown of the
holinergic neuronal system is probably most extensively studied
euronal system among the different neurotransmitter systems in
D pathology. Obviously, the normal turnover and renewal of neu-
onal structures, ﬁrst of all synapses, escapes physiological control
rocesses, especially in response to the increased formation of beta
myloid (A) peptides and tau phosphorylation. The result is that
here are not only less and less cholinergic ﬁbers in the target cor-
ical areas as shown in Fig. 1, but also that the remaining synapses
re deteriorated. These observations may lead to the conclusion
hat structural and functional aberrations of synapses are one of
he primary pathological events in AD (Fig. 2).
A42 triggers cholinergic dysfunction by promoting aberrant
euritic sprouting [42]. While, in general, GAP-43 immunoreac-
ivity as a marker of sprouting is decreased in the cortical areas
f AD brain, aberrant sprouting is accompanied by intense GAP-
3 production in response to A peptides [44]. Aberrant sprouting
ight lead to the formation of other pathologies, like ﬁber swelling
nd swollen proﬁles forming grape-like structures [20]. The abnor-
al appearanceof sprouting cholinergic ﬁbers and their underlying
rocesses may be interpreted as an adaptive restorative response
s a preliminary stage of subsequent neuritic degeneration.
The appearance of aberrant ﬁbers and ﬁber swelling are more
nd more pronounced during brain aging and widely common in
D. It was found that A inhibits the fast axonal transport of vesic-
lar ACh transporter (VAChT). This ﬁnding supports the idea that
ajor aspects of AD neuropathology results of failures in axonal
ransport [31],which is alsoendorsedby the impairedmicrotubule-
ased neuronal transport pathways during the progression of AD.
eversely, the reduction of microtubule-dependent axonal trans-
ort may stimulate pathological cleavage of APP resulting in A
eposition and plaque formation [66].
It was shown in neuronal cell culture experiment that ﬁber
welling was coupled with axonal transport block in response
o exposure to A ﬁbrils [63]. Such observations suggest that an
mportant cause of the formation of ﬁber swelling of cholinergic
eurons in aging and AD will be the axonal transport block ormuch less ﬁbers are present and even these ﬁbers contain lot of enlarged boutons
he normal sized en passant boutons pointed by black arrows can be found in both
is 50m.
pathological slowdownof themolecular transportprocesses.More-
over, the chronic deterioration of intra-axonal transport capacity of
cholinergicneuronsand their cortical projections canbeconsidered
as hazard that could promote the degeneration of the BFChS in AD
in a retrograde fashion. It has been demonstrated that axonal fast
transport,which is critical for normal neuronal functioning is inhib-
ited by A peptide oligomers, which cause bidirectional axonal
transport inhibition as a consequence of endogenous casein kinase
2 activation [58]. Furthermore these authors showed that neither
nonaggregated nor ﬁbrillar amyloid beta A affected axonal fast
transport which makes understandable why the oligomeric form
of A proves to be the most neurotoxic.
Many neurodegenerative diseases exhibit axonal pathology,
transport defects, and aberrant phosphorylation and aggregation
of the microtubule binding protein tau. Regarding axonopathy
processes directly interfering with axonal transport are sufﬁ-
cient to activate stress kinase pathways initiating a biochemical
cascade that drives normal tau protein into the pathological hyper-
phosphorylated state [15] which is a prominent feature of AD
neuropathology.
It may be concluded that axonal pathologies including abnor-
mal accumulations of proteins and organelles within the swollen
structures point to the importance of axonal transport in a neu-
rodegenerative disease likeAD [14]. In thedirect vicinity of amyloid
depositions and amyloid plaques the pathologic malformations of
neuritic ﬁbers are most prominent, often designated as dystrophic
neurites [28,55,57,65]. With respect to cholinergic cortical ﬁber
pathology such aberrations are not exclusively conﬁned to the neu-
ritic plaquedomainandpresent all over the corticalmantle [20] and
most likely a stage representing ongoing destruction of the BFChS.
1.5. The glutamatergic overexcitation theory of AD progression-Amyloid peptide 1–42, the principal constituent of the neu-
ritic plaques seen in Alzheimer’s disease (AD) patients, is known
to trigger excess amount of glutamate in the synaptic cleft by
inhibiting the astroglial glutamate transporter and to increase the
C. Nyakas et al. / Behavioural Brain R
Fig. 2. Camera lucida drawings of the cholinergic innervation pattern in a strip of
























of A induced neuronal and neuritic injury and concomitant cogni-ontrol case. AChE staining. Numbers refer to the various cortical layers. Grey dots
n the right panel indicate the presence of amyloid plaques.
ntracellular Ca2+ level [24] through enhancement of NMDA recep-
or activity [49]. Other mechanisms leading to excitotoxicity may
nclude the inductionof oxidative stress and thedirect impact of A
n the glutamatergic NMDA receptor [9,34,43]. Whatever the pre-
ise underlying pathogenic processes, overstimulation of the nerve
ell by glutamate and intracellular calciumaccumulationwill even-
ually cause neuronal apoptosis, disrupt synaptic plasticity (e.g.,
ong-term potentiation, LTP) [34], and as a result of such dysregu-
ation will profoundly impair learning and memory functions.
If synaptic concentration of glutamate is overbalanced, overex-
itation of postsynaptic neurons may lead to cellular stress which
s especially demanding if the energy maintenance of that neurons
s compromised. During aging, and especially during pathological
ging a number of endotoxic metabolic factors are bombarding
he neurons (hypoxia, ischemia, insulin resistance, oxygen radi-
als, etc.) in addition to the genetic predisposition to pathological
ntracellular molecular events. Under these progressing condi-
ion during aging overexcitation of neurons by glutamate may
e considered as one of the options to ﬁnd pharmacological tar-
ets [36,72]. The pathogenesis of degenerative neural disorders
ncluding stroke, head and spinal-cord trauma, and chronic neu-
odegenerative diseases like Alzheimer’s disease have all beenesearch 221 (2011) 594–603 597
linked to excitotoxic processes due to inappropriate overstimula-
tion of the N-methyl-d-aspartate (NMDA) receptor [9,36].
1.6. NMDA receptor antagonists in AD treatment
Based on the glutamatergic overexcitation theory of AD pro-
gression for a long period of time a number of NMDA receptor
antagonists served as candidates for clinical treatment. Previous
attempts to use high afﬁnity NMDA receptor antagonists as neuro-
protectants have been hindered by serious side-effects in patients.
The leading principle for any optimal drug is to develop well tol-
erated and effective compounds which should interact with their
target only during states of pathological activation but should
not interfere with the target if it functions physiologically [37].
Memantine, a moderate afﬁnity uncompetitive NMDA receptor
antagonist meets this requirement and does not interfere with
the normal NMDA receptor function [10,73]. Memantine is well
tolerated and shows clinically relevant efﬁcacy in patients with
Alzheimer’s disease and preferentially blocks excessive NMDA
receptor activitywithout disrupting normal activity. It slows cogni-
tive, behavioral and functional (activities of daily living) decline and
attenuates agitation/aggression and delusion in AD patients and
is approved for the treatment of moderate to severe Alzheimer’s
disease [61,68,17]. The mechanisms by which memantine exerts
its beneﬁcial effects in AD are under continuous further investi-
gation. Besides Alzheimer’s disease and even Parkinson’s disease,
memantine is currently in trials for additional neurological disor-
ders, including other forms of dementia, depression, glaucoma, and
severe neuropathic pain [35]. In experimental studies beyond the
cognitive enhancing effect memantine exerts an anxiolytic type of
action [48], which opens further indications for future therapy.
In experimental studies memantine has been shown to provide
neuroprotection and improves performance using several phar-
macological models of impaired learning and memory [36]. It has
been shown to reduce the secretion of A peptides in primary
fetal rat cortical neurons [1], in human neuroblastoma cells [60]
and in triple-transgenic AD model mice [41]. Memantine improves
hippocampus-based learning in APP/PS1 double-transgenic mice
with higher than normal levels of brain A42 and formation of A
plaques [47,41].
In this study, we report the neuroprotective effects of meman-
tine in rats with multiple A42 oligomer injections into the
cholinergic nucleus basalis magnocellularis (MBN) and neocortex.
1.7. Aˇ induced BFChS degeneration as an in vivo animal test
model
In the present paper we have shortly reviewed the particu-
lar breakdown of the basal forebrain cholinergic system in aging
and specially in Alzheimer’s disease. The prominent breakdown of
this system in AD prompted us to employ the damage and loss
of cholinergic neurons and their forebrain projection induced by
A exposure as an in vivo test model to evaluate the neuroprotec-
tive potential of drugs or other treatments for therapeutic purposes
in AD. There are a number of reasons to adapt to such a model.
First of all the breakdown of cholinergic forebrain innervations
is particularly relevant to AD neuropathology. Second, the loss of
BFChS components in AD can be speciﬁcally be associated with
cognitive decline characterized byderangement ofmemory perfor-
mance, loss of learning capacity, and impaired behavioral attention
[57,53,54]. Thirdly, our detailed knowledge of this transmitter sys-
tem in the rodent brain allows highly reproducible quantiﬁcationtive deﬁcits, which allows assessment of neuroprotective potential
of novel drug treatment as measured on neuronal system rescue
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Recently, the pathology of A has been correlated to oligomeric
orms of the peptide which is the most neurotoxic form in the
ine of aggregated metabolic products (for review see [71]). A
ligomers destroy dendritic spines and are involved in the NMDA
eceptor-mediated intracellular toxicity [64]. In the present paper
e will report our ﬁndings of the neuroprotective effects of the
MDA channel antagonist memantine in this in vivo rodent model
pplying A oligomers as neurotoxin.
. Protection of cholinergic neurons against A-induced
xcitotoxicity by NMDA antagonist memantine
In theabovechaptersof Section1 thevulnerabilityof cholinergic
eurons in AD, the A induced overexcitation of neurons includ-
ng cholinergic types and the neuroprotective action of memantine
gainst A related pathologies were highlighted. Up till now,
owever, no study has been performed directly investigating the
utative neuroprotective effect of memantine on the forebrain
holinergic neurons against A induced toxicity. In this in vivo
tudy we investigated the neuroprotective and behavioral effects
f memantine in an advanced dementia model of A42 oligomers-
nduced cholinergic toxicity. We report that memantine rescues
heneocortical cholinergicﬁbers and improves attentionandmem-
ry of A42-injected rats exhibiting impaired learning and loss of
holinergic innervation of neocortex.
.1. Animals and memantine drug treatment
Male Harlan Wistar rats weighing 250–280g outbred in our
aboratory were used in this study. During the experiment
nimals were kept under normal laboratory conditions in an air-
onditioned room (21±2 ◦C)with a 12/12h light–dark cycle (lights
n from 07.00 a.m. to 07.00 p.m.) with food and tap water ad libi-
um. The animal experiments were carried out in accordance with
heEuropeanCommunityCouncilDirectivedirective86/609 for the
are and use of laboratory animals and were approved by the local
nstitutional Scientiﬁc Ethical Committee at the University.
Memantine (Forest Research Institute, Jersey City, NJ, USA)
as administered orally through drinking water at a dose of
5mg/kg/day starting 3 days before surgery and continued
hroughout 10 days postsurgery. The solution was replaced every
ay and the daily memantine intake was controlled by adjusting
he concentration in the drinking water according to individual
ater consumption. A separate pilot study preceding the main
xperiment was undertaken to determine the therapeutic dose of
emantine producing a steady-state plasma drug level of around
M in rat. This concentration corresponds to the human ther-
peutic dose. The per os dose of 35mg/kg/day was selected and
dministered in the drinking water throughout the entire exper-
ment. In the pilot study the plasma levels of memantine were
nalyzed using a gas-chromatographic system coupledwith amass
pectrometer [33].
.2. Surgery and Aˇ1–42 injection into the brain
Surgery was performed as described in [38]. The animals were
nesthetized with Nembutal (sodium pentobarbital, 60mg/kg i.p.)
nd placed in a stereotaxic frame (Narishige, Japan). The neurotox-
city of A has been attributed to oligomeric conformations of the
eptide [71,58], and additional studies indicate an involvement of
heNMDA receptor also in A-oligomer toxicity [64]. As oligomeric
 is now thought to underlie the pathology of the disease,we gen-
rated A oligomers in vitro and used this oligomer preparation –
ather than the monomeric or polymeric forms of the peptide – to
nduce acetylcholinergic degeneration in the MBN in rats. Blottingesearch 221 (2011) 594–603
analysis showed mainly dimer and trimer conformations as major
constituents of the injected amyloid solution [23].
Injections of A42 oligomers in a concentration of 1g/l
vehicle were performed into the right MBN and in the right fron-
toparietal neocortex at the rate of 0.1l/min. Into both anatomical
locations 2 times 0.5l injections were delivered. The rationale
for the double injections was to mimic the multiple anatomical
A depositions characteristic in the brain of Alzheimer’s disease.
The atlas of [56] was used for the stereotectic coordinates of the
two injections: AP: Bregma −1.0 and −1.6; L 2.5 and 3.4; and for
deepness of injections the two anatomical sites were differently
approached: MBN 6.9, cortex 1.3 from the dura at both injection
sites. The oligomeric A42 was prepared according to [12] and as
described in detail elsewhere [23].
2.3. Behavioral testing
All behavioral tests were performed blindly and the individ-
ual animals from the different groups and cages were selected
randomly for the testing. The test arenas were observed through
an optical camera positioned 1.5m above the arenas, which also
allowed to carry out video recording. By this way the experimen-
tal animals could not see the experimenter. The behavioral tests
started 3 days after operation.
2.3.1. Novel object recognition
It served to test attention ability in a novel environment. On
postsurgery day 3 the animals were habituated to handling and
transport to the experimental room and to an open-ﬁeld appara-
tus where the novel object recognition test was carried out next
day as described earlier by us [53]. The test included two sessions.
During the 1st session the rats were allowed to explore the same
open-ﬁeld arena for 5min while two identical objects were placed
in an asymmetric position with respect to the center of the arena.
These objects became familiar objects. After a 4-h inter-session
interval spent in the home-cage, the rats were replaced into the
open-ﬁeld arena for the 2nd session that lasted another 5min. Dur-
ing the 2nd session one of the familiar objects was replaced by
a markedly different object. The time (in s) spent on visiting the
objects were recorded. The total time of visits towards both objects
served as measure of general exploratory activity. The measure of
novel object recognition was the percentage of time exploring the
novel object divided by total time spent exploring both the novel
and familiar objects. Fiftypercent represented thechance levelwith
no discrimination or no recognition of novelty.
2.3.2. One-way step-through passive avoidance learning
For the passive shock-avoidance conditioned response test a
two-compartment (one-way) step-through apparatus was used
[54]. The behavioral procedure started at 6th day after surgery and
lasted for 3 days. In the initial trial at the ﬁrst day the rats were
placed in an illuminated chamber lit by a 40W bulb and allowed to
explore the apparatus. The latency to enter the dark compartment
was recorded (1st trial latency). On the second day of experimen-
tal schedule the animals were placed again on the lit platform
and allowed to entry freely into the dark compartment (2nd trial).
During the 3rd trial after entering the dark compartment a mild
foot-shock (0.8mA, 3 s) was delivered through the grid ﬂoor and
the rats were returned into their home-cage afterwards. The reten-
tion test was performed 24h later and the latency to step into the
dark chamber was recorded (postshock latency) within a total of a
5-min retesting period.2.4. Brain tissue analysis
Brain ﬁxation was carried out at postoperative days





























































2.5.2. Behavioral effects: passive avoidance learning
Latency of entering the dark box 24h after the learning trial was
different among thegroups (F4,64 = 4.49,p<0.005) causedmainlyby
Fig. 3. Results on exploration of objects in a habituated open-ﬁeld arena (upper
panel) anddiscrimination betweennovel versus familiar objects (novel object recog-
nition, lower panel) are shown. Groups are: intact, sham-operated, sham-operated
and memantine-treated (sham+Mem), A42-injected (Abeta), and A42-injectedC. Nyakas et al. / Behavioural B
uffered saline (PBS) pH7.4 followed by 4% paraformaldehyde
Sigma–Aldrich, Hungary) solution containing 0.05% glutaralde-
yde (Sigma–Aldrich, Hungary) in 0.1M phosphate buffer (PB
H7.4) after adequate deep pentobarbital anaesthesia. After
ostﬁxation of the brains for 48h in the same ﬁxative the brains
ere stored in 0.1M PB containing 0.1% Na-azide until histological
xaminations. For histological processing the brains were cryopro-
ected by storage in 30% sucrose and sectioned in a Leica cryostat
icrotome at a thickness of 20m to obtain coronal sections at
he AP level of lesioned areas.
.4.1. Cholinergic ﬁber innervation: staining and quantiﬁcation
Immunostaining procedure on free ﬂoating coronal sections
as applied to visualize choline acetyltransferase (ChAT) positive
holinergic neurons inMBN and their axon ramiﬁcations in the tar-
et brain areas, i.e. in the parietal neocortex. The primary antibody
as a goat anti-ChAT (AB144P, Chemicon) which was used in a
ilution rate of 1:500 to visualize cholinergic ﬁbers [27]. Biotiny-
ated rabbit anti-goat IgG andVectastain ABC kitwas obtained from
ector Laboratories (CA, USA). The staining was completed with
ickel-enhanced diaminobenzidine (DAB) reaction in the presence
f H2O2.
The quantiﬁcation procedure for cholinergic ﬁber density is
stablished in our laboratory and was described in greater detail
reviously [26,24]. Brieﬂy, parietal neocortex, topographically cor-
esponding to the anterior–posterior site of the A42 lesion in the
BN and with the highest level of cholinergic ﬁber loss were ana-
yzed for ﬁber density with the Quantimet 600HR (Leica, Germany)
mage analysis program. The exact measurement took place in the
uperﬁcial sublayer of the layer V cortical area which receives high
ensity of cholinergic innervation. Three brains sections were ana-
yzed per animal and the results averaged. Fiber density expressed
n percent surface area of positively stained ﬁbers were computed
n both sides of the brain sections. The ChAT positive ﬁber density
psilateral to the lesion was compared to the intact contralateral
ide and the percentage loss was calculated as an indicator of
holinergic neuron and ﬁber loss.
.4.2. Activated microglia: staining and magnitude of microglia
eaction
The antibody against the integrin CD11b was selected to label
ctivated microglia. In the control brain baseline level activity of
icroglia is minimal and hardly visible after immunocytochemical
taining. Microglia activation becomes markedly enhanced in and
round the lesion or degeneration of the nervous tissue. Mouse
nti-rat CD11b (MAB1405Z, Chemicon), as primary antibody in a
ilution rate of 1:1000 was used in the microglia immunoassay.
he biotinylated secondary horse anti-mouse antibody and theABC
it were obtained from Vector Labs (USA, see above) and used in
:500 dilution rate. DAB (3,3′-diamino benzidine, Sigma) reaction
as enhanced by nickel ammonium sulfate as described above.
Microglial activation was localized remarkably in and around
he lesions and could be quantiﬁed with a computerized tech-
ique measuring the size of the brain region inﬁltrated by the
ctivatedmicroglia (Quantimet, Leica). Areaofmicroglial activation
as manually delineated and measured in the MBN and neocortex
t the anterior–posterior level of the overstained injection channel.
ere again three sections were selected for measurements. Selec-
ion of sections and the measurements were unbiased and carried
ut blindly.
Comparing different treatment groups one-way ANOVA was
pplied, followed by the Dunnett post hoc t-test comparing two
roups. All statistical analyses were performed with Statistica 8.0
oftware. The statistical signiﬁcance was set at p<0.05. Means and
tandard errors of means (SEM) are presented to demonstrate the
esults.esearch 221 (2011) 594–603 599
2.5. Effects of memantine on Aˇ-induced cholinergic
degeneration
2.5.1. Behavioral effects: novel object recognition
The results are shown in Fig. 1. With one-way ANOVA no
difference could be obtained among groups in exploration of
objects in general: F4,64 = 1.06, p=0.38, which shows that the
exploratory behavior per se was not inﬂuenced by the treatments
or the lesion (see upper panel). By analyzing the discrimina-
tion capability between novel versus familiar objects one-way
ANOVA revealed a signiﬁcant difference among groups (F4,64 = 4.21,
p<0.005). A42-injected animals performed close to the chance,
i.e. ﬁfty percent level. Post hoc analysis of attention abilities
between paired groups showed that against A42 injection group
(Abeta) both sham+memantine (p<0.01) and A42+memantine
(p<0.05) groups performed better. Memantine treatment, there-
fore, was preventive against the A42 oligomers-induced lesion
effect. Sham-lesioned rats treated with memantine were not dif-
ferent from the sham control animals.and memantine-treated (Abeta +Mem). The number of animals in the groups var-
ied from 10 to 18. ANOVA revealed no difference in exploration but signiﬁcant
group differences in novel object recognition: F4,64 = 4.21, p<0.005. Post hoc Dun-
nett test showed a difference between groups of Abeta and sham control (*p<0.05).
Differences against Abeta group are indicated by #p<0.05 and ##p<0.01.
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Fig. 4. Memoryexpressedas latencyof entering thedark shock-compartment tested
in the passive avoidance learning paradigm is shown. Groups are: intact, sham-
operated, sham-operated and memantine-treated (sham+Mem), A42-injected
(Abeta), and A42-injected and memantine-treated (Abeta +Mem). The number of
animals in the groups varied from 10 to 18. Entering latency 24h after the learning
trial (electric foot-shock) was signiﬁcantly shorter in the A42-injected (Abeta) rats
against the sham control group (*p<0.05). The performance of Abeta-injected and
memantine-treated group was signiﬁcantly better as that of Abeta group. ##p<0.01
signiﬁcant difference from Abeta.
Fig. 5. Attenuation of cholinergic lesion caused by A42-injections into the regions of nuc
In microphotograph B (upper right panel) the ipsilateral injection tracks are shown in cort
the ChAT positive ﬁber quantiﬁcations were performed (black arrow). The graph shows
lesions. Abeta (A42 oligomers) injection increased ﬁber loss against sham control (**p<0.
neural damage (##p<0.01 versus Abeta group). Two rows of photomicrographs below sh
ﬁber loss in the cortex compared to sham controls at the left. A42-injected and memanti
the cholinergic neurons are located and in the cortex where the forebrain cholinergic neuesearch 221 (2011) 594–603
the A42 injection (Fig. 2). Retention of passive avoidance learning
responsewas diminished after A42 injection versus shamcontrols
(p<0.05). The A42-lesioned animals differed signiﬁcantly against
other two groups including A42-injected+memantine-treated
animals (p<0.01). The A42-injected and memantine-treated ani-
mals performed the task indistinguishable from sham controls. In
this behavioral test like in thenovel object recognition testmeman-
tine prevented the behavioral deﬁcit caused by amyloid peptide
injection. Memantine treatment alone, in sham-lesioned rats, did
not change the learning performance.
2.5.3. Memantine effects on the cholinergic lesion
The A42-induced cholinergic ﬁber loss in the ipsilateral
parietal neocortex was attenuated by memantine (Fig. 3A). One-
way ANOVA showed a difference among groups (F3,55 = 10.09,
p<0.001). Paired comparisons are also shown in the ﬁgure, i.e.
A42 injection caused a signiﬁcant 19.6% loss of cholinergic ﬁbers
(p<0.001), memantine pre- and postlesion treatments attenuated
this effect by 72% (p<0.005). The ﬁber loss in the A42-injected
and memantine-treated group was not different from that of sham
control. Sham animals treated with memantine were not differ-
ent from sham controls. The photomicrographs of representative
animals in Fig. 3 show the density of ChAT positive magnocellular
neurons in the MBN and their corresponding axon arborizations in
the parietal neocortex. A42 treatment resulted in a loss of ChAT
positive neurons in MBN and a decreased cholinergic ﬁber density
leus basalismagnocellularis (NBM) and neocortex byNMDA antagonistmemantine.
ex and nucleus basalis next to the area (white box) in the parietal neocortex where
the degree of cholinergic ﬁber loss in the cortex as a result of the nucleus basalis
01), while additionalmemantine treatment largely attenuated the amyloid induced
ow the degree of ChAT positive neuronal loss in response to A in the NBM and a
ne-treated rats represent an attenuated lesion effect shown both in the NMB where
rons project unilaterally.
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Fig. 6. Area of microglial activation evoked by amyloid peptide-induced lesion in the cortex and nucleus basalis magnocellularis (NBM). The upper part of the ﬁgure shows
in columns that A42 increased the activated area in both regions (**p<0.01), and memantine interfered with this effect signiﬁcantly: differences against the Abeta group:





























Aontrol, Abeta (A42)-injected, and peptide-injected and memantine treated. A
emantine interfered with this effect (photo at the right) and reduced the size of m
n the neocortex. Memantine treatment attenuated both the loss of
eurons and the loss of ﬁbers.
.5.4. Memantine effects on microglia activation
The A42-induced lesion and also the sham-lesion resulted in
icroglia activation detected by immunostaining of the activity
arker CD11b (Fig. 4). The upper graphs show the immunoreactive
reas ofmicroglia activation in percentage of sham controls in both
he cortex and in MBN. The lower three photomicrographs are rep-
esentative pictures demonstrating the extend of activation areas
n sham, A42-injected (Abeta) and A42-injected+memantine-
reated groups. The Abeta lesion increased the size of microglia
ctivation around the injection channels in both the cortex and
BN. The quantitative data on the graphs show that the amyloid
eptide treatment increased the activation area in both anatom-
cal regions: cortex: F3,55 = 11.62, p<0.001; MBN: F3,55 = 16.23,
< 0.001. Comparing Abeta and sham groups with post hoc test
esulted in signiﬁcant differences (p<0.01). Memantine treatment
arkedly attenuated this effect in the cortex (p<0.05) and practi-
allyprevented it in theMBN(p<0.01).Memantine treatmentalone
n sham animals did not change the degree of microglia activation
ompared to sham controls (Figs. 5 and 6).
. Discussion
In the presently applied A42 lesionmodel, cholinergic neurons
riginating from the magnocellular basal nucleus (MBN) showed
igniﬁcant axonal degeneration in the parietal neocortex. A42
ligomers also enhanced microglial reaction around the lesion site
oth in the MBN and in the neocortex. Treatment with a ther-
peutically relevant dose of memantine signiﬁcantly attenuated
42-induced loss of cholinergic ﬁbers and microglia activationreased the activated area represented by the middle photo in both regions and
lia activation.
in the neocortex and MBN. Memantine also reversed the attention
and learning deﬁcits in the A42-treated rats.
Thesedata indicate theabilityofmemantine to rescuebrain cells
from the neurotoxic in vivo effect of A42 oligomers. Oral treat-
ment ofmemantinewas continuous for 3 days before A injections
and during the entire postsurgery period of 10 days. Thus, molec-
ular actions of memantine on NMDA receptors and on a number of
neuronal protective mechanisms should be taken into account to
explain the present ﬁndings. Regarding the diffusion of intracere-
brally injected peptide oligomers we have found that the diameter
of A peptide inﬁltration approached 2.0mm in the nervous tissue
1h after injection which gradually declined by the 3rd postinjec-
tion day allowing approximately 48h exposure of the neurotoxin
(unpublished data). Based on our previous ﬁndings [24] and ﬁnd-
ingsof others asdiscussed indetail in theabove sectionof this paper
“The glutamatergic overexcitation theory of AD progression”, we
propose that memantine attenuated the postsynaptic glutamater-
gic overexcitation of the NMDA receptor leading to an attenuation
of the increase of the intracellular Ca2+ concentration.
A is known to exert a number of cellular and molecular
pathologies leading to cognitive deﬁcits, LTP disruption (disruption
of synaptic plasticity), oxidative stress and apoptosis as sum-
marised above.Memantine can interferewith all these pathological
processes. It improves learning and memory in entorhinal cortex
lesioned [74] and aged [8] rats and improves spatial learning in
APP/PS1 transgenic [47] and triple-transgenic AD mice [41] over-
expressingA.Memantine increases themaintenance of long-term
potentiation in the hippocampus of old rats [8] and of transgenic
mice overexpressing A [41]. In addition it prevents A-evoked
decrease in hippocampal somatostatin and substance P level, two
neuropeptides that otherwise support LTP in the hippocampus
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icroglia andastrocytes and theactivationof induciblenitric-oxide
ynthase were also signiﬁcantly attenuated by memantine treat-
ent. A number of authors have suggested that theNMDA receptor
ediates the pathological effect of A oligomers in vitro [64,32,13].
n addition, memantine is able to inhibit truncation of glycogen
ynthase kinase-3 triggered by activated calpain, which is believed
o play a key role in the pathogenesis of Alzheimer’s disease and
otably the process of tau phosphorylation [22]. Calpain, a calcium
ependent cysteine protease, is a downstream link of the NMDA
eceptor-induced neurodegeneration pathway [51]. These results
ll suggest that the neuroprotective effect of memantine found in
his study had to be largely mediated through the stabilization of
MDA receptor function.However, it cannot be excluded that there
ight be other, NMDA independent neuroprotective pathways
perated by memantine which could potentiate its neuroprotec-
ive type of action in the present study. Along this line it may be
entioned that there are reports showing thatmemantine reduces
erotonergic 5-HT3 receptor-mediated inward currents in a same
oncompetitive manner as for blocking of NMDA receptors [59],
hich action may add to the cognition enhancing effect of meman-
ine. In addition,memantine canevokeneurotrophic typesof action
s well as was shown in cell culture experiments [76]. In this
tudy the neurotrophic effect of memantine could be observed as
ncreased production of glial cell line-derived neurotrophic factor
GDNF) in astroglia. In addition, memantine also displays neu-
oprotective effects against LPS-induced dopaminergic neuronal
amage through inhibition of microglia activation as showed by
oth integrin alphaM (OX-42) immunostaining, and reduction of
ro-inﬂammatory factor production. The latter include extracellu-
ar superoxide anions, intracellular reactive oxygen species, nitric
xide, prostaglandin E2, and tumor necrosis factor- [76]. In that
espect we observed in the present experiments a reduced acti-
ation of microglia in response to memantine treatment which
orroborates this ﬁnding.
In summary, in a novel in vivo dementia model applying toxic
ligomers of beta amyloid peptide 1–42 into different brain areas
ncluding the basal cholinergic forebrain region a neuroprotective
ction of memantine has been demonstrated. Memantine rescued
holinergic neurons and their efferentation to the neocortex, and
ttenuated the lesion-induced attention and learning deﬁcit. In
ddition the drug treatment reduced the activation of microglia
round the lesion sides in the NBM and neocortex, which may be
ither the result of the decreased neuronal degeneration or a direct
ffect of memantine on microglia. Our data for the ﬁrst time show
hat memantine may improve cognition by protecting cholinergic
eurons from A toxicity.
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